About Invea Therapeutics
Invea Therapeutics is a private company based in Guilford, Connecticut, incorporated in 2021 in Delaware. It has reported $1,945,244 raised in three offerings on Form D since April 2022. Its chief executive is Krishnan Nandabalan.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 31, 2025 | Dec 10, 2025 | $120,250fully sold | 1 | $120K | Equity, OptionsRule 506(b) | Form D ↗ |
| Mar 31, 2025 | Apr 9, 2025 | $300,000of $600K target | 2 | $150K | Debt, Convertible promissory notesRule 506(b) | Form D ↗ |
| Apr 7, 2022 | Apr 22, 2022 | $1,524,994of $5.7M target | 4 | $381K | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $1,945,244 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Invea Therapeutics's Form D filed Dec 10, 2025.
DK
Demetrios Kydonieus
Director
AK
Aman Kant
President
SA
Salvatore Alesci
Chief Scientific Officer
MA
Michael Aiello
Chief Financial Officer
JZ
Jonathan Zalevsky
Director
SO
Shunichiro "Steve" Okada
Chief Medical Officer
SD
Stephen Doberstein
Director
KB
Kerrie Brady
Director
KN
Krishnan Nandabalan
Chief Executive Officer and Chairman
Earlier filings also listed Vimal Mehta (director, last listed Apr 2022) and Sandeep Laumas (director, last listed Apr 2022).